Home ETF List About

Portfolio Holdings Detail for ISIN IE00BF4RFH31
Stock Name / FundiShares MSCI World Small Cap UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares III Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300PZLRJB7M8H1057
ETF TickerWSML(USD) LSE
ETF TickerWLDS(GBP) LSE
ETF TickerIUSN(EUR) F
ETF TickerIUSN.DE(EUR) CXE
ETF TickerWLDS.LS(GBP) CXE
ETF TickerWSML.LS(USD) CXE
ETF TickerWSML.L(GBP) LSE
ETF TickerWLDS.L(GBP) LSE

Holdings detail for MRUS

Stock NameMerus BV
TickerMRUS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINNL0011606264

Show aggregate MRUS holdings

News associated with MRUS

Merus N.V. (NASDAQ:MRUS) Receives Average Recommendation of “Buy” from Analysts
Merus N.V. (NASDAQ:MRUS – Get Free Report) has received an average recommendation of “Buy” from the twelve research firms that are covering the firm, Marketbeat.com reports. Eleven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that […] - 2025-09-04 03:06:58
Merus (NASDAQ:MRUS) Coverage Initiated at Alliance Global Partners
Research analysts at Alliance Global Partners started coverage on shares of Merus (NASDAQ:MRUS – Get Free Report) in a research note issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $90.00 price target on the biotechnology company’s stock. Alliance Global Partners’ target price suggests a potential upside of 34.61% from the […] - 2025-08-27 02:30:45
Leerink Partnrs Estimates Merus’ Q3 Earnings (NASDAQ:MRUS)
Merus N.V. (NASDAQ:MRUS – Free Report) – Analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for Merus in a report issued on Wednesday, August 6th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of ($1.50) for the quarter, down from their prior estimate of ($1.32). […] - 2025-08-12 02:46:48
Merus (NASDAQ:MRUS) Downgraded to Sell Rating by Wall Street Zen
Merus (NASDAQ:MRUS – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Sunday. A number of other research analysts have also issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $75.00 […] - 2025-07-22 02:07:06
Wall Street Zen Upgrades Merus (NASDAQ:MRUS) to “Hold”
Merus (NASDAQ:MRUS – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. A number of other brokerages have also issued reports on MRUS. William Blair reaffirmed an “outperform” rating on shares of Merus in a research report on […] - 2025-07-14 03:40:50
Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock
Merus N.V. (NASDAQ:MRUS – Get Free Report) COO Peter B. Silverman sold 34,000 shares of the firm’s stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $52.76, for a total value of $1,793,840.00. The sale was disclosed in a legal filing with the SEC, which is accessible […] - 2025-06-27 05:10:52
Merus N.V. (NASDAQ:MRUS) Receives $84.64 Average Price Target from Brokerages
Merus N.V. (NASDAQ:MRUS – Get Free Report) has been assigned a consensus rating of “Buy” from the fourteen analysts that are currently covering the firm, MarketBeat reports. Twelve equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price […] - 2025-06-24 02:36:57
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 14,544 Shares of Merus (NASDAQ:MRUS)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Merus (NASDAQ:MRUS – Free Report) by 17.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 98,744 shares of the biotechnology company’s stock after purchasing an additional 14,544 shares […] - 2025-06-05 05:13:00
Merus Prices 5.26 Mln Shares At $57/Shr In Public Offering; To Raise Around $300 Mln
(RTTNews) - Merus N.V. (MRUS), a Dutch oncology company developing multispecific antibodies and antibody drug conjugates, Wednesday announced the pricing of an underwritten public offering of around 5.26 million shares, at a price of $57.00 per share. The gross proceeds from the - 2025-06-04 01:56:43
Merus N.V. Announces Pricing of $300 Million Public Offering of Common Shares
Merus N.V. announced a $300 million public offering of 5.26 million common shares to fund clinical development and research. - 2025-06-04 01:20:22
Analysts Anticipate 25% Gains Ahead For The Holdings of FHLC
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-05-29 08:03:59
Merus (NASDAQ:MRUS) Earns Buy Rating from Needham & Company LLC
Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $75.00 target price on the biotechnology company’s stock. Needham & Company LLC’s price target points to a potential upside […] - 2025-05-21 03:03:18
Merus (NASDAQ:MRUS) Holdings Decreased by The Manufacturers Life Insurance Company
The Manufacturers Life Insurance Company reduced its stake in shares of Merus (NASDAQ:MRUS – Free Report) by 17.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,085 shares of the biotechnology company’s stock after selling 9,204 shares during the quarter. […] - 2025-05-12 05:36:50
Tudor Investment Corp ET AL Purchases Shares of 5,075 Merus (NASDAQ:MRUS)
Tudor Investment Corp ET AL bought a new stake in Merus (NASDAQ:MRUS – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,075 shares of the biotechnology company’s stock, valued at approximately $213,000. A number of other institutional investors and hedge […] - 2025-05-11 05:44:52
Tower Research Capital LLC TRC Decreases Stock Holdings in Merus (NASDAQ:MRUS)
Tower Research Capital LLC TRC decreased its stake in shares of Merus (NASDAQ:MRUS – Free Report) by 77.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,668 shares of the biotechnology company’s stock after selling 9,221 shares during the […] - 2025-05-09 05:21:09
Merus (NASDAQ:MRUS) Short Interest Update
Merus (NASDAQ:MRUS – Get Free Report) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,270,000 shares, a decrease of 15.5% from the March 31st total of 7,420,000 shares. Currently, 9.6% of the company’s shares are sold short. Based on […] - 2025-05-05 04:58:56
Merus (NASDAQ:MRUS) Earns “Outperform” Rating from William Blair
William Blair reaffirmed their outperform rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report issued on Monday morning,RTT News reports. Several other analysts have also commented on the stock. Guggenheim reissued a “buy” rating and set a $109.00 target price on shares of Merus in a research note on Friday, March 28th. […] - 2025-04-29 04:54:48
Invesco Ltd. Grows Stock Position in Merus (NASDAQ:MRUS)
Invesco Ltd. lifted its holdings in Merus (NASDAQ:MRUS – Free Report) by 2.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 786,365 shares of the biotechnology company’s stock after purchasing an additional 16,712 shares during the period. Invesco Ltd. owned about 1.15% of Merus […] - 2025-04-18 05:18:50
HighTower Advisors LLC Has $337,000 Stock Position in Merus (NASDAQ:MRUS)
HighTower Advisors LLC lifted its position in Merus (NASDAQ:MRUS – Free Report) by 10.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,020 shares of the biotechnology company’s stock after buying an additional 789 shares during the period. HighTower […] - 2025-04-02 04:14:47
Guggenheim Reiterates Buy Rating for Merus (NASDAQ:MRUS)
Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a report issued on Tuesday,Benzinga reports. They presently have a $109.00 target price on the biotechnology company’s stock. Guggenheim’s price objective indicates a potential upside of 131.91% from the company’s previous close. Other research analysts also recently […] - 2025-03-20 04:55:00
Bank of America Has Lowered Expectations for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its target price lowered by analysts at Bank of America from $73.00 to $70.00 in a note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective indicates a potential upside of 47.12% from the […] - 2025-03-12 04:00:48
HC Wainwright Reaffirms “Buy” Rating for Merus (NASDAQ:MRUS)
Merus (NASDAQ:MRUS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $85.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 90.41% from the stock’s previous close. […] - 2025-03-05 04:32:51
William Blair Predicts Merus’ FY2028 Earnings (NASDAQ:MRUS)
Merus (NASDAQ:MRUS – Free Report) – William Blair issued their FY2028 EPS estimates for Merus in a report issued on Friday, February 28th. William Blair analyst M. Phipps expects that the biotechnology company will post earnings per share of ($3.58) for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate […] - 2025-03-04 06:28:57
Merus (NASDAQ:MRUS) Given New $83.00 Price Target at Needham & Company LLC
Merus (NASDAQ:MRUS – Free Report) had its price objective lowered by Needham & Company LLC from $85.00 to $83.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. A number of other equities analysts have also recently commented on the company. The Goldman […] - 2025-03-03 04:54:51
Merus (NASDAQ:MRUS) Shares Purchased by State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D grew its holdings in shares of Merus (NASDAQ:MRUS – Free Report) by 29.0% during the 4th quarter, HoldingsChannel reports. The firm owned 48,268 shares of the biotechnology company’s stock after buying an additional 10,842 shares during the period. State of New Jersey Common Pension Fund D’s holdings […] - 2025-02-24 06:42:49
Analysts Set Merus (NASDAQ:MRUS) PT at $85.92
Shares of Merus (NASDAQ:MRUS – Get Free Report) have been assigned a consensus recommendation of “Buy” from the sixteen research firms that are covering the stock, MarketBeat reports. Fourteen equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month price […] - 2025-02-19 04:46:55
KBC Group NV Has $2.41 Million Stake in Merus (NASDAQ:MRUS)
KBC Group NV raised its position in Merus (NASDAQ:MRUS – Free Report) by 4,583.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,234 shares of the biotechnology company’s stock after purchasing an additional 56,012 shares during the quarter. KBC Group NV’s holdings in […] - 2025-02-02 07:28:57

iShares MSCI World Small Cap UCITS ETF USD (Acc) MRUS holdings

DateNumber of MRUS Shares HeldBase Market Value of MRUS SharesLocal Market Value of MRUS SharesChange in MRUS Shares HeldChange in MRUS Base ValueCurrent Price per MRUS Share HeldPrevious Price per MRUS Share Held
2025-10-15 (Wednesday)36,364USD 3,452,762USD 3,452,762
2025-10-10 (Friday)36,145USD 3,411,004USD 3,411,004
2025-10-08 (Wednesday)36,145USD 3,411,365USD 3,411,365
2025-10-07 (Tuesday)36,145MRUS holding increased by 146USD 3,411,727MRUS holding increased by 18101USD 3,411,727146USD 18,101 USD 94.39 USD 94.27
2025-10-06 (Monday)35,999USD 3,393,626MRUS holding decreased by -720USD 3,393,6260USD -720 USD 94.27 USD 94.29
2025-10-03 (Friday)35,999USD 3,394,346MRUS holding increased by 5040USD 3,394,3460USD 5,040 USD 94.29 USD 94.15
2025-10-02 (Thursday)35,999USD 3,389,306USD 3,389,3060USD 0 USD 94.15 USD 94.15
2025-10-01 (Wednesday)35,999USD 3,389,306USD 3,389,3060USD 0 USD 94.15 USD 94.15
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of MRUS by Blackrock for IE00BF4RFH31

Show aggregate share trades of MRUS

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-07BUY146 94.390* 50.35
2025-09-08SELL-292 67.190* 48.66 Profit of 14,209 on sale
2025-08-15BUY146 67.250* 48.56
2025-08-07BUY438 63.390* 48.38
2025-07-29BUY146 65.920* 47.77
2025-07-14BUY292 55.620* 47.26
2025-06-30BUY296 52.600* 46.99
2025-06-25BUY438 53.880* 46.87
2025-06-20SELL-74 53.105* 46.75 Profit of 3,459 on sale
2025-06-12SELL-592 55.390* 46.48 Profit of 27,513 on sale
2025-06-02BUY222 58.530* 45.88
2025-05-28BUY148 50.010* 45.71
2025-05-14BUY74 40.400* 45.74
2025-05-13BUY148 40.920* 45.78
2025-05-07BUY222 39.430* 45.92
2025-04-28BUY74 45.280* 46.03
2025-04-16BUY962 41.910* 46.25
2025-04-14BUY148 42.430* 46.31
2025-04-08SELL-148 34.890* 46.60 Profit of 6,896 on sale
2025-04-04SELL-150 38.110* 46.77 Profit of 7,015 on sale
2025-03-28BUY740 44.610* 46.95
2025-03-12SELL-148 49.160* 46.93 Profit of 6,946 on sale
2025-03-04SELL-148 44.640* 46.97 Profit of 6,952 on sale
2025-02-26SELL-296 45.530* 47.02 Profit of 13,917 on sale
2025-02-13BUY76 40.300* 47.43
2025-02-12BUY300 40.260* 47.54
2025-01-27BUY75 40.400* 48.97
2025-01-23BUY75 41.110* 49.25
2024-12-09BUY2,196 43.740* 49.84
2024-12-04BUY122 45.485* 50.17
2024-12-03BUY183 46.210* 50.25
2024-11-19BUY366 43.490* 52.04
2024-11-18BUY122 44.270* 52.28
2024-11-12BUY240 51.630* 52.30
2024-11-11BUY60 52.960* 52.25
2024-11-11BUY60 52.960* 52.25
2024-11-07BUY300 54.500* 51.91
2024-11-07BUY300 54.500* 51.91
2024-10-23BUY120 52.310* 52.39
2024-10-23BUY120 52.310* 52.39
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MRUS

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19123,75515,565295,32441.9%
2025-09-1897,3164,160228,73742.5%
2025-09-17144,3271,098242,46559.5%
2025-09-16109,9602,131222,43449.4%
2025-09-15149,8900318,67947.0%
2025-09-12313,4555,537606,03651.7%
2025-09-11186,04117,755345,08153.9%
2025-09-1077,2990149,18451.8%
2025-09-09109,27712,250231,07547.3%
2025-09-08110,3000207,99053.0%
2025-09-05113,7432,003270,19242.1%
2025-09-0471,3900194,43536.7%
2025-09-03118,2361,764269,03743.9%
2025-09-02104,542485304,73834.3%
2025-08-2988,408602208,72042.4%
2025-08-28205,6791,769570,45436.1%
2025-08-2743,7270107,17140.8%
2025-08-2649,2210280,42017.6%
2025-08-2551,1610113,71745.0%
2025-08-22100,1567,575192,11152.1%
2025-08-2172,4115,956216,04233.5%
2025-08-2059,6600265,38522.5%
2025-08-1994,8490242,81639.1%
2025-08-1849,3072,689113,53643.4%
2025-08-1564,98410,335112,73357.6%
2025-08-1476,8440278,92427.6%
2025-08-13178,5061,001423,47642.2%
2025-08-1286,7181,133254,30134.1%
2025-08-1184,695390117,68072.0%
2025-08-08112,4221,666230,83448.7%
2025-08-07130,196179222,63858.5%
2025-08-06255,4360409,27962.4%
2025-08-05102,3195,000286,82235.7%
2025-08-0443,196067,78863.7%
2025-08-01111,3330277,02240.2%
2025-07-31164,449300435,71737.7%
2025-07-30114,7390179,11064.1%
2025-07-2969,9870152,83345.8%
2025-07-28117,8630253,63746.5%
2025-07-25170,5300303,99956.1%
2025-07-24254,6644,904482,53052.8%
2025-07-23145,1700217,50366.7%
2025-07-22139,563525302,77646.1%
2025-07-21287,1341,374573,96150.0%
2025-07-18269,9230465,09658.0%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.